Cargando…
Decreased Heart Rate Variability in COVID-19
PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713139/ https://www.ncbi.nlm.nih.gov/pubmed/36471860 http://dx.doi.org/10.1007/s44231-022-00024-1 |
_version_ | 1784841949096706048 |
---|---|
author | Yin, Chengfen Li, Jianguo Wang, Zhiyong Zhi, Yongle Xu, Lei |
author_facet | Yin, Chengfen Li, Jianguo Wang, Zhiyong Zhi, Yongle Xu, Lei |
author_sort | Yin, Chengfen |
collection | PubMed |
description | PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. This report aimed to highlight decreased heart rate variability (HRV) and cardiac injury caused by SARS-CoV-2. MATERIALS AND METHODS: We evaluated three COVID-19 patients who died. Patients’ data were collected from electronic medical records. We collected patient’s information, including baseline information, lab results, body temperature, heart rate (HR), clinical outcome and other related data. We calculated the HRV and the difference between the expected and actual heart rate changes as the body temperature increased. RESULTS: As of March 14, 2020, 3 (2.2%) of 136 patients with COVID-19 in Tianjin died in the early stage of the COVID-19 epidemic. The immediate cause of death for Case 1, Case 2, and Case 3 was cardiogenic shock, cardiac arrest and cardiac arrest, respectively. The HRV were substantially decreased in the whole course of all three cases. The actual increases in heart rate were 5 beats/min, 13 beats/min, and 4 beats/min, respectively, less than expected as their temperature increased. Troponin I and Creatine Kinase MB isoenzyme (CK-MB) were substantially increased only in Case 3, for whom the diagnosis of virus-related cardiac injury could not be made until day 7. In all three cases, decreased in HRV and HR changes occurred earlier than increases in cardiac biomarkers (e.g., troponin I and CK-MB). CONCLUSIONS: In conclusion, COVID-19 could affect HRV and counteract tachycardia in response to increases in body temperature. The decreases of HRV and HR changes happened earlier than the increases of myocardial markers (troponin I and CK-MB). It suggested the decreases of HRV and HR changes might help predict cardiac injury earlier than myocardial markers in COVID-19, thus its early identification might help improve patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s44231-022-00024-1. |
format | Online Article Text |
id | pubmed-9713139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-97131392022-12-01 Decreased Heart Rate Variability in COVID-19 Yin, Chengfen Li, Jianguo Wang, Zhiyong Zhi, Yongle Xu, Lei Intensive Care Res Case Report PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. This report aimed to highlight decreased heart rate variability (HRV) and cardiac injury caused by SARS-CoV-2. MATERIALS AND METHODS: We evaluated three COVID-19 patients who died. Patients’ data were collected from electronic medical records. We collected patient’s information, including baseline information, lab results, body temperature, heart rate (HR), clinical outcome and other related data. We calculated the HRV and the difference between the expected and actual heart rate changes as the body temperature increased. RESULTS: As of March 14, 2020, 3 (2.2%) of 136 patients with COVID-19 in Tianjin died in the early stage of the COVID-19 epidemic. The immediate cause of death for Case 1, Case 2, and Case 3 was cardiogenic shock, cardiac arrest and cardiac arrest, respectively. The HRV were substantially decreased in the whole course of all three cases. The actual increases in heart rate were 5 beats/min, 13 beats/min, and 4 beats/min, respectively, less than expected as their temperature increased. Troponin I and Creatine Kinase MB isoenzyme (CK-MB) were substantially increased only in Case 3, for whom the diagnosis of virus-related cardiac injury could not be made until day 7. In all three cases, decreased in HRV and HR changes occurred earlier than increases in cardiac biomarkers (e.g., troponin I and CK-MB). CONCLUSIONS: In conclusion, COVID-19 could affect HRV and counteract tachycardia in response to increases in body temperature. The decreases of HRV and HR changes happened earlier than the increases of myocardial markers (troponin I and CK-MB). It suggested the decreases of HRV and HR changes might help predict cardiac injury earlier than myocardial markers in COVID-19, thus its early identification might help improve patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s44231-022-00024-1. Springer Netherlands 2022-12-01 2023 /pmc/articles/PMC9713139/ /pubmed/36471860 http://dx.doi.org/10.1007/s44231-022-00024-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Case Report Yin, Chengfen Li, Jianguo Wang, Zhiyong Zhi, Yongle Xu, Lei Decreased Heart Rate Variability in COVID-19 |
title | Decreased Heart Rate Variability in COVID-19 |
title_full | Decreased Heart Rate Variability in COVID-19 |
title_fullStr | Decreased Heart Rate Variability in COVID-19 |
title_full_unstemmed | Decreased Heart Rate Variability in COVID-19 |
title_short | Decreased Heart Rate Variability in COVID-19 |
title_sort | decreased heart rate variability in covid-19 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713139/ https://www.ncbi.nlm.nih.gov/pubmed/36471860 http://dx.doi.org/10.1007/s44231-022-00024-1 |
work_keys_str_mv | AT yinchengfen decreasedheartratevariabilityincovid19 AT lijianguo decreasedheartratevariabilityincovid19 AT wangzhiyong decreasedheartratevariabilityincovid19 AT zhiyongle decreasedheartratevariabilityincovid19 AT xulei decreasedheartratevariabilityincovid19 |